A group of researchers Massachusetts Institute of Technology (MIT) He developed a new experimental strategy that allowed a drug to combat arthrosis by accessing and internalizing the cartilage of the joints. This progress in rats is a step to achieve a treatment that slows the progression of an incurable disease to this day.
Arthrosis is a progressive degeneration of cartilage of joints caused by aging or injury. This disease affects approximately 300 million people worldwide and there is no inverse, because cartilage is a non-regenerable tissue. Although there are therapies that can alleviate the symptoms of osteoarthritis, there is no treatment to slow progression.
One of the challenges of treatment is that drugs cannot easily enter the cartilage. It is removed from the joints or does not enter the cartilage before the most effect, the place where the cells producing it, the chondrocytes, so that they cannot perform their functions.
Therefore, the researchers designed a nanocouple, a molecule that can be inserted into cartilage and acting as a tool that can carry drugs to chondrocytes. The molecule consists of a spherical portion from which the drug binds, branch-like structures with a positive electrical charge, and a compound called PEG.
Because cartilage has a negative charge, the positive charges of the nantransporter cause it to stick to the tissue. On the other hand, PEG permits a transition from the cartilage to reach the chondrocytes.
According to the journal Science Translation MedicineScientists, cartilage production and the growth and growth of chondrocytes to stimulate the function of the nanocarrier & IGF-1 added to the drug. To test this assay, the nanocarrier was injected into the knee joints of rats with osteoarthritis without injury.
This treatment reduced cartilage degeneration, inflammation and the appearance of bone changes. Likewise, with a nanocarrier, the half-life of the drug in the joints is multiplied by ten. In addition, this was maintained at effective concentrations in the cartilage for thirty days, so potentially every two weeks or monthly injection would be sufficient.
O It's a very interesting study, I says Josep Vergés, president and doctor of the International Osteoarthritis Foundation (OAFI), who was not involved in the study.
According to Vergés, if applied to humans and effective in mice, it could improve the quality of life of patients, because it would be sufficient once or twice a month. However, it is still necessary to see whether it has been confirmed in clinical trials. He added that it may take four to eight years for the drug to be available on the market.